A broad-spectrum caspase inhibitor blocks concanavalin A-induced hepatitis in mice

Clinical Immunology

Volumn 97, Issue 3, 2000, Pages 221-233

  Kim, Kwang Mi ^a   Kim, Young Myeong ^b   Park, Mijeong ^c   Park, Kiwon ^c   Chang, Hye Kyung ^c   Park, Tae Kyo ^c   Chung, Hyun Ho ^c   Kang, Chang Yuil ^a  

^a Seoul National University   (South Korea)

^b Kangwon National University   (South Korea)

^c LG Chemical Ltd   (South Korea)

Author keywords

Apoptosis; Caspase inhibitor; Con A induced hepatitis; Fulminant hepatic failure

Indexed keywords

ALANINE AMINOTRANSFERASE; CASPASE INHIBITOR; CONCANAVALIN A; DNA FRAGMENT; INTERLEUKIN 1BETA; XYS 033;

ACUTE PHASE RESPONSE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; EXPERIMENTAL INFECTION; GENE MAPPING; HISTOPATHOLOGY; LIVER CELL; LIVER FAILURE; LIVER PROTECTION; LIVER TOXICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TOXIC HEPATITIS;

EID: 0033663873     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2000.4939     Document Type: Article

References (75)

1. The management of fulminant hepatic failure
2. Fulminant and subfulminant liver failure: Clinical, serological and histological features
3. Late onset hepatic failure: Clinical, serological and histological features
4. Fulminant hepatic failure
5. Fulminant hepatic failure
6. Fulminant hepatic failure
7. Acute liver failure: Complications and current management
8. Management of fulminant hepatic failure
9. Apoptosis in the pathogenesis and treatment of disease
10. ICE/CED3-like proteases as therapeutic targets for the control of inappropriate apoptosis
11. Apoptosis and viral hepatitis
12. Fas systemapoptosis in viral hepatitis
13. Is Apoptosis involved in alcoholic hepatitis? Alcohol Alcohol
14. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95(APO-1/Fas) mediated apoptosis
15. Apoptosis in the human liver during allograft rejection and end-stage liver disease
16. Caspases: The executioners of apoptosis
17. Caspases: Enemies within
18. Caspases: Intracellular signaling by proteolysis
19. Activation of caspases in lethal experimental hepatitis and prevention by acute phase proteins
20. A T cell-dependent experimental liver injury in mice inducible by concanavalin A
21. T cell activation-associated hepatic injury: Mediation by tumor necrosis factors and protection by interleukin 6
22. Immunotoxicology of T cell-dependent experimental liver injury
23. Involvement of Fas/Fas ligand system-mediated apoptosis in the development of concanavalin A-induced hepatitis
24. Disparate roles for TNF-alpha and Fas ligand in concanavalin A-induced hepatitis
25. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A
26. IL-6, IFN-gamma and TNF-alpha production by liver-associated T cells and acute liver injury in rats administered concanavalin A
27. In vivo evidence for a functional role of both tumor necrosis factor (TNF) receptors and transmembrane TNF in experimental hepatitis
28. - T cells for concanavalin A-induced hepatic injury in mice
29. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice
30. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase
31. Nonheme iron-nitrosyl complex formation in rat hepatocytes: Detection by electron paramagnetic resonance spectroscopy
32. Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms
33. Hepatitis B virus biology and pathogenesis
34. The expression of IL-2, IL-4 and interferon-7 (IFN-γ) mRNA using liver biopsies at different phases of acute exacerbation of chronic hepatitis B
35. Tumor necrosis factor alpha production by peripheral blood mononuclear cells of patients with chronic liver disease
36. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis
37. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis
38. Caenorhabditis elegans CED-9 protein is a bifunctional cell-death inhibitor
39. Conversion of Bcl-2 to a Bax-like death effector by caspases
40. Cleavage of lamin A by Mch2 alpha but not CPP32: Multiple interleukin 1 beta-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis
41. Caspase-3-generated fragment of gelsolin: Effector of morphological change in apoptosis
42. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2
43. Viral inhibition of inflammation: Cowpox virus encodes an inhibitor of the interleukin-1 beta converting enzyme
44. Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35
45. Conservation of baculovirus inhibitor of apoptosis repeat proteins (BIRPs) in viruses, nematodes, vertebrates and yeasts
46. The hepatitis B virus HBx protein inhibits caspase 3 activity
47. Distinct steps in DNA fragmentation pathway during camptothecin-induced apoptosis involved caspase-, benzyloxycarbonyl- and N-tosyl-L-phenylalanylchloromethyl ketone-sensitive activities
48. ICE-protease inhibitors block murine liver injury and apoptosis caused by CD95 or by TNF-alpha
49. Systemic injection of a tripeptide inhibits the intracellular activation of CPP32-like proteases in vivo and fully protects mice against Fas-mediated fulminant liver destruction and death
50. ICE inhibitor YVADcmk is a potent therapeutic agent against in vivo liver apoptosis
51. A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis
52. BCNU is a caspase-mediated inhibitor of drug-induced apoptosis
53. COX 2 inhibitor and fulminant hepatic failure
54. Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death
55. Cloning and expression of the cDNA encoding rat caspase-2
56. Galaco tosamine-induced sensitization to the lethal effect of endotoxin
57. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice
58. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen
59. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A
60. TCR/CD3 coupling to Fas-based cytotoxicity
61. Lethal effect of the anti-Fas antibody in mice
62. Identification of intrahepatic lymphocyte subpopulations in patients with fulminant hepatitis by the immunoenzymatic technique, using monoclonal antibodies
63. Essential roles of the Fas ligand in the development of hepatitis
64. Mechanisms of class I restricted immunopathology: A transgenic mouse model of fulminant hepatitis
65. Fas-mediated apoptosis in primary cultured mouse hepatocytes
66. Fas antigen expression in liver tissues of patients with chronic hepatitis B
67. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C
68. Contribution of Fas ligand to T-cell mediated hepatic injury in mice
69. Augmentation of Vα14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis
70. Caspase activation is required for T cell proliferation
71. Cloning of a new cytokine that induces IFN-gamma production by T cells
72. Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production
73. Activation of interferon-gamma inducing factor mediated by interleukin- 1beta converting enzyme
74. Interleukin-18 regulation of interferon gamma production and cell proliferation as shown in interleukin-1 betaconverting enzyme (caspase-1)-deficient mice
75. Caspase-1-independent, Fas/Fas ligand-mediated IL-18 secretion from macrophages causes acute liver injury in mice